Autonomix Medical has been granted a US patent covering its platform for diagnosing and treating overactive bladder. The patent, issued by the US Patent and Trademark Office, expands the company's neural sensing and therapeutic technology into the urology market, where overactive bladder affects an estimated 37 million Americans. The platform supports a catheter-based, minimally invasive approach that detects abnormal bladder nerve activity and delivers targeted therapy such as radiofrequency ablation or localized drug delivery, with real-time electrophysiological feedback to verify treatment effectiveness. The patent also covers an implantable bladder device for long-term monitoring of bladder pressure and electrophysical signals. CEO Brad Hauser said the patent strengthens the company's intellectual property portfolio in nerve-targeted therapies.
Autonomix Medical, Inc. Common StockGranted US patent covering its platform for diagnosing and treating overactive bladder, expanding neural sensing and therapeutic technology into urology market.